UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 1017, 2026

SKYE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-55136

45-0692882

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)


11250 El Camino Real, Suite 100, San Diego, CA 92130
(Address of principal executive offices)


(858) 410-0266
(Registrant’s telephone number, including area code)

_________________________


(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001

SKYE

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 23.0201 ~~Results~~Notice of ~~Operations~~Delisting ~~and~~or ~~Financial~~Failure ~~Conditions~~to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 1017, 2026, Skye Bioscience, Inc. (the “Company” or “Skye”) ~~issued~~received a ~~press~~deficiency ~~release~~letter ~~reporting~~from ~~its~~the ~~financial~~Nasdaq ~~results~~Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the ~~fourth~~last ~~quarter~~30 ~~and~~consecutive ~~full~~business ~~year~~days, ~~ended~~the ~~December 31~~closing bid price for the Company’s common stock, ~~2025~~par value $0. 001 per share (the “Common Stock”) had been below the minimum $1.00 per share required for continued listing on The ~~full~~Nasdaq ~~text~~Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (“Rule 5450(a)(1)”). The Nasdaq deficiency letter has no immediate effect on the listing of the ~~press~~Company’s ~~release~~Common isStock, ~~attached~~and asthe ~~Exhibit~~Common ~~99.1~~Stock towill ~~this~~continue ~~Current~~to ~~Report~~trade on ~~Form~~The ~~8-K~~Nasdaq Global Market under the symbol “SKYE” at this time.

In accordance with ~~General~~Nasdaq ~~Instruction~~Listing ~~B.2~~Rule ~~of Form 8-K~~5810(c)(3)(A), the ~~information~~Company ~~contained~~has orbeen ~~incorporated~~given ~~herein,~~180 ~~including~~calendar ~~the~~days, ~~press~~or ~~release~~until ~~filed~~September as14, ~~Exhibit 99.1~~2026, ~~shall~~to ~~not~~regain becompliance ~~deemed~~with ~~“filed”~~Rule ~~for~~5450(a)(1). ~~purposes~~If ofthe ~~Section~~Company 18chooses ofto ~~the~~implement ~~Securities~~a ~~Exchange~~reverse ~~Act~~stock ~~of 1934~~split, asit ~~amended~~must (complete the ~~“Exchange~~split ~~Act”),~~no orlater ~~otherwise~~than ~~subject~~ten tobusiness ~~the~~days ~~liabilities~~prior ofto ~~that~~September ~~section~~14, ~~nor~~2026, ~~shall~~to itregain becompliance. ~~deemed~~If toat beany ~~incorporated~~time bybefore ~~reference~~September ~~into~~14, ~~any~~2026, ~~filing under~~ the ~~Securities~~bid ~~Act~~price of ~~1933,~~the asCommon ~~amended,~~Stock orcloses ~~the~~at ~~Exchange~~$1.00 ~~Act,~~per ~~whether~~share ~~made before~~ or ~~after~~more ~~the~~for ~~date~~a ~~hereof,~~minimum ~~except~~of as10 ~~expressly~~consecutive ~~set~~business ~~forth~~days, bythe ~~specific~~Staff ~~reference~~will inprovide ~~such~~written ~~filing~~confirmation tothat ~~this~~the ~~Current~~Company ~~Report~~has onregained ~~Form 8-K~~compliance.

~~Item~~If 9the Company does not regain compliance with Rule 5450(a)(1) by September 14, 2026, the Company may be afforded a second 180 calendar day period to regain compliance.01 ~~Financial~~To ~~Statements~~qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and ~~Exhibits~~all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period.

The Company intends to actively monitor the closing bid price for the Common Stock and will consider available options to resolve the deficiency and regain compliance with Rule 5450(da)(1). ~~Exhibits~~However, there can be no assurance that the Company will be able to regain compliance with the Rule 5450(a)(1) or will otherwise be in compliance with other Nasdaq Listing Rules.

Exhibit No.						Description
99.1						Press Release, dated March 10, 2026
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SKYE BIOSCIENCE, INC.
Dated: March 10, 2026			/s/ Punit Dhillon
Dated: March 19, 2026			/s/ Punit Dhillon
			Name: Punit Dhillon
			Title: Chief Executive Officer

Filing Compare · Skye Bioscience, Inc.